Skip to main content

Advertisement

SpringerLink
Log in

Medical and Surgical Treatment Options for Nonalcoholic Steatohepatitis

  • Review
  • Published:
Digestive Diseases and Sciences Aims and scope Submit manuscript

Abstract

Nonalcoholic fatty liver disease (NAFLD) is the most common cause of liver disease in the USA with a growing prevalence worldwide. Nonalcoholic steatohepatitis (NASH), progressive form of NAFLD, can lead to the development of cirrhosis, hepatocellular carcinoma, and the need for liver transplantation. Treatment of NASH may decrease the risk of progressive disease. Treatment for NAFLD should center around weight loss and exercise. Pharmacotherapy with vitamin E and pioglitazone should be considered for those with NASH, especially those with fibrosis. Weight loss surgery is also an effective treatment for NASH in individuals with other indications for surgery. In this review, we will discuss the currently available therapies for NASH including lifestyle, pharmacologic, and surgical options.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Browning JD, Szczepaniak LS, Dobbins R, et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology. 2004;40:1387–1395. doi:10.1002/hep.20466.

    Article  PubMed  Google Scholar 

  2. Loomba R, Sanyal AJ. The global NAFLD epidemic. Nat Rev Gastroenterol Hepatol. 2013;10:686–690. doi:10.1038/nrgastro.2013.171.

    Article  CAS  PubMed  Google Scholar 

  3. Charlton M. Cirrhosis and liver failure in nonalcoholic fatty liver disease: Molehill or mountain? Hepatology. 2008;47:1431–1433. doi:10.1002/hep.22246.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Angulo P, Kleiner DE, Dam-Larsen S, et al. Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology. 2015;149:389.e10–397.e10. doi:10.1053/j.gastro.2015.04.043.

    Article  Google Scholar 

  5. Pais R, Charlotte F, Fedchuk L, et al. A systematic review of follow-up biopsies reveals disease progression in patients with non-alcoholic fatty liver. J Hepatol. 2013;59:550–556. doi:10.1016/j.jhep.2013.04.027.

    Article  CAS  PubMed  Google Scholar 

  6. McPherson S, Hardy T, Henderson E, Burt AD, Day CP, Anstee QM. Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: implications for prognosis and clinical management. J Hepatol. 2015;62:1148–1155. doi:10.1016/j.jhep.2014.11.034.

    Article  PubMed  Google Scholar 

  7. Kleiner DE, Brunt EM, Van Natta M, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005;41:1313–1321. doi:10.1002/hep.20701.

    Article  PubMed  Google Scholar 

  8. Brunt EM, Kleiner DE, Wilson LA, Belt P, Neuschwander-Tetri BA, Network NCR. Nonalcoholic fatty liver disease (NAFLD) activity score and the histopathologic diagnosis in NAFLD: distinct clinicopathologic meanings. Hepatology. 2011;53:810–820. doi:10.1002/hep.24127.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Sanyal AJ, Brunt EM, Kleiner DE, et al. Endpoints and clinical trial design for nonalcoholic steatohepatitis. Hepatology. 2011;54:344–353. doi:10.1002/hep.24376.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Promrat K, Kleiner DE, Niemeier HM, et al. Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis. Hepatology. 2010;51:121–129. doi:10.1002/hep.23276.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Harrison SA, Fecht W, Brunt EM, Neuschwander-Tetri BA. Orlistat for overweight subjects with nonalcoholic steatohepatitis: a randomized, prospective trial. Hepatology. 2009;49:80–86. doi:10.1002/hep.22575.

    Article  CAS  PubMed  Google Scholar 

  12. Vilar-Gomez E, Martinez-Perez Y, Calzadilla-Bertot L, et al. Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis. Gastroenterology. 2015;149:367 e5–378 e5. doi:10.1053/j.gastro.2015.04.005. (quiz e14–5).

    PubMed  Google Scholar 

  13. Kirk E, Reeds DN, Finck BN, Mayurranjan SM, Patterson BW, Klein S. Dietary fat and carbohydrates differentially alter insulin sensitivity during caloric restriction. Gastroenterology. 2009;136:1552–1560. doi:10.1053/j.gastro.2009.01.048.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Tendler D, Lin S, Yancy WS Jr, et al. The effect of a low-carbohydrate, ketogenic diet on nonalcoholic fatty liver disease: a pilot study. Dig Dis Sci. 2007;52:589–593. doi:10.1007/s10620-006-9433-5.

    Article  CAS  PubMed  Google Scholar 

  15. Browning JD, Baker JA, Rogers T, Davis J, Satapati S, Burgess SC. Short-term weight loss and hepatic triglyceride reduction: evidence of a metabolic advantage with dietary carbohydrate restriction. Am J Clin Nutr. 2011;93:1048–1052. doi:10.3945/ajcn.110.007674.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Ryan MC, Itsiopoulos C, Thodis T, et al. The Mediterranean diet improves hepatic steatosis and insulin sensitivity in individuals with non-alcoholic fatty liver disease. J Hepatol. 2013;59:138–143. doi:10.1016/j.jhep.2013.02.012.

    Article  CAS  PubMed  Google Scholar 

  17. Estruch R, Ros E, Salas-Salvado J, et al. Primary prevention of cardiovascular disease with a Mediterranean diet. N Engl J Med. 2013;368:1279–1290. doi:10.1056/NEJMoa1200303.

    Article  CAS  PubMed  Google Scholar 

  18. Mayes PA. Intermediary metabolism of fructose. Am J Clin Nutr. 1993;58:754S–765S.

    CAS  PubMed  Google Scholar 

  19. Havel PJ. Dietary fructose: implications for dysregulation of energy homeostasis and lipid/carbohydrate metabolism. Nutr Rev. 2005;63:133–157.

    Article  PubMed  Google Scholar 

  20. Elliott SS, Keim NL, Stern JS, Teff K, Havel PJ. Fructose, weight gain, and the insulin resistance syndrome. Am J Clin Nutr. 2002;76:911–922.

    CAS  PubMed  Google Scholar 

  21. Ouyang X, Cirillo P, Sautin Y, et al. Fructose consumption as a risk factor for non-alcoholic fatty liver disease. J Hepatol. 2008;48:993–999.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Maersk M, Belza A, Stodkilde-Jorgensen H, et al. Sucrose-sweetened beverages increase fat storage in the liver, muscle, and visceral fat depot: a 6-mo randomized intervention study. Am J Clin Nutr. 2012;95:283–289. doi:10.3945/ajcn.111.022533.

    Article  CAS  PubMed  Google Scholar 

  23. Vos MB, Weber MB, Welsh J, et al. Fructose and oxidized low-density lipoprotein in pediatric nonalcoholic fatty liver disease: a pilot study. Arch Pediatr Adolesc Med. 2009;163:674–675. doi:10.1001/archpediatrics.2009.93.

    Article  PubMed  PubMed Central  Google Scholar 

  24. StGeorge A, Bauman A, Johnston A, Farrell G, Chey T, George J. Independent effects of physical activity in patients with nonalcoholic fatty liver disease. Hepatology. 2009;50:68–76.

    Article  CAS  Google Scholar 

  25. Sullivan S, Kirk EP, Mittendorfer B, Patterson BW, Klein S. Randomized trial of exercise effect on intrahepatic triglyceride content and lipid kinetics in nonalcoholic fatty liver disease. Hepatology. 2012;55:1738–1745. doi:10.1002/hep.25548.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Johnson NA, Sachinwalla T, Walton DW, et al. Aerobic exercise training reduces hepatic and visceral lipids in obese individuals without weight loss. Hepatology. 2009;50:1105–1112. doi:10.1002/hep.23129.

    Article  CAS  PubMed  Google Scholar 

  27. Oh S, Tanaka K, Tsujimoto T, So R, Shida T, Shoda J. Regular exercise coupled to diet regimen accelerates reduction of hepatic steatosis and associated pathological conditions in nonalcoholic fatty liver disease. Metab Syndr Relat Disord. 2014;12:290–298. doi:10.1089/met.2013.0143.

    Article  CAS  PubMed  Google Scholar 

  28. Hallsworth K, Fattakhova G, Hollingsworth KG, et al. Resistance exercise reduces liver fat and its mediators in non-alcoholic fatty liver disease independent of weight loss. Gut. 2011;60:1278–1283. doi:10.1136/gut.2011.242073.

    Article  PubMed  PubMed Central  Google Scholar 

  29. Bacchi E, Negri C, Targher G, et al. Both resistance training and aerobic training reduce hepatic fat content in type 2 diabetic subjects with nonalcoholic fatty liver disease (the RAED2 Randomized Trial). Hepatology. 2013;58:1287–1295. doi:10.1002/hep.26393.

    Article  CAS  PubMed  Google Scholar 

  30. Slentz CA, Bateman LA, Willis LH, et al. Effects of aerobic vs. resistance training on visceral and liver fat stores, liver enzymes, and insulin resistance by HOMA in overweight adults from STRRIDE AT/RT. Am J Physiol Endocrinol Metab. 2011;301:E1033–E1039. doi:10.1152/ajpendo.00291.2011.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Keating SE, Hackett DA, George J, Johnson NA. Exercise and non-alcoholic fatty liver disease: a systematic review and meta-analysis. J Hepatol. 2012;57:157–166. doi:10.1016/j.jhep.2012.02.023.

    Article  CAS  PubMed  Google Scholar 

  32. Hoofnagle JH, Van Natta ML, Kleiner DE, et al. Vitamin E and changes in serum alanine aminotransferase levels in patients with non-alcoholic steatohepatitis. Aliment Pharmacol Ther. 2013;38:134–143. doi:10.1111/apt.12352.

    Article  CAS  PubMed  Google Scholar 

  33. Sanyal AJ, Chalasani N, Kowdley KV, et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med. 2010;362:1675–1685.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Neuschwander-Tetri BA, Loomba R, Sanyal AJ, et al. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. Lancet. 2015;385:956–965. doi:10.1016/S0140-6736(14)61933-4.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Loomba R, Sirlin CB, Ang B, et al. Ezetimibe for the treatment of nonalcoholic steatohepatitis: assessment by novel magnetic resonance imaging and magnetic resonance elastography in a randomized trial (MOZART trial). Hepatology. 2015;61:1239–1250. doi:10.1002/hep.27647.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Kowdley KV, Wilson L, Van Natta ML, Pai RK, Sanyal AJ. Efficacy and Safety of Vitamin E in Nonalcoholic Steatohepatitis Patients With and Without Diabetes: Pooled Analysis from the PIVENS and FLINT NIDDK NASH CRN Trials. Presented at the American Association for the Study of Liver Disease, The Liver Meeting, San Francisco, CA; 2015 (Abstract ID: 107).

  37. Klein EA, Thompson IM Jr, Tangen CM, et al. Vitamin E and the risk of prostate cancer: the selenium and vitamin E cancer prevention trial (SELECT). JAMA. 2011;306:1549–1556. doi:10.1001/jama.2011.1437.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Gaziano JM, Glynn RJ, Christen WG, et al. Vitamins E and C in the prevention of prostate and total cancer in men: the Physicians’ Health Study II randomized controlled trial. JAMA. 2009;301:52–62. doi:10.1001/jama.2008.862.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Lippman SM, Klein EA, Goodman PJ, et al. Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the selenium and vitamin E cancer prevention trial (SELECT). JAMA. 2009;301:39–51. doi:10.1001/jama.2008.864.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. Miller ER 3rd, Pastor-Barriuso R, Dalal D, Riemersma RA, Appel LJ, Guallar E. Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality. Ann Intern Med. 2005;142:37–46.

    Article  CAS  PubMed  Google Scholar 

  41. Belfort R, Harrison SA, Brown K, et al. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med. 2006;355:2297–2307. doi:10.1056/NEJMoa060326.

    Article  CAS  PubMed  Google Scholar 

  42. Aithal GP, Thomas JA, Kaye PV, et al. Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis. Gastroenterology. 2008;135:1176–1184. doi:10.1053/j.gastro.2008.06.047.

    Article  CAS  PubMed  Google Scholar 

  43. Musso G, Gambino R, Cassader M, Pagano G. Meta-analysis: natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity. Ann Med. 2011;43:617–649.

    Article  PubMed  Google Scholar 

  44. Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology. 2012;55:2005–2023. doi:10.1002/hep.25762.

    Article  PubMed  Google Scholar 

  45. Neuschwander-Tetri BA, Brunt EM, Wehmeier KR, Oliver D, Bacon BR. Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-gamma ligand rosiglitazone. Hepatology. 2003;38:1008–1017. doi:10.1053/jhep.2003.50420.

    Article  CAS  PubMed  Google Scholar 

  46. Lincoff AM, Wolski K, Nicholls SJ, Nissen SE. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA. 2007;298:1180–1188. doi:10.1001/jama.298.10.1180.

    Article  CAS  PubMed  Google Scholar 

  47. Ratziu V. Pharmacological agents for NASH. Nat Rev Gastroenterol Hepatol. 2013;10:676–685. doi:10.1038/nrgastro.2013.193.

    Article  CAS  PubMed  Google Scholar 

  48. Lewis JD, Ferrara A, Peng T, et al. Risk of bladder cancer among diabetic patients treated with pioglitazone: interim report of a longitudinal cohort study. Diabetes Care. 2011;34:916–922. doi:10.2337/dc10-1068.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  49. Nesto RW, Bell D, Bonow RO, et al. Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. October 7, 2003. Circulation. 2003;108:2941–2948. doi:10.1161/01.CIR.0000103683.99399.7E.

    Article  PubMed  Google Scholar 

  50. Dormandy JA, Charbonnel B, Eckland DJ, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet. 2005;366:1279–1289. doi:10.1016/S0140-6736(05)67528-9.

    Article  CAS  PubMed  Google Scholar 

  51. Van Wagner LB, Koppe SW, Brunt EM, et al. Pentoxifylline for the treatment of non-alcoholic steatohepatitis: a randomized controlled trial. Ann Hepatol. 2011;10:277–286.

    PubMed  Google Scholar 

  52. Zein CO, Lopez R, Fu X, et al. Pentoxifylline decreases oxidized lipid products in nonalcoholic steatohepatitis: new evidence on the potential therapeutic mechanism. Hepatology. 2012;56:1291–1299. doi:10.1002/hep.25778.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  53. Zein CO, Yerian LM, Gogate P, et al. Pentoxifylline improves nonalcoholic steatohepatitis: a randomized placebo-controlled trial. Hepatology. 2011;54:1610–1619. doi:10.1002/hep.24544.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  54. Athyros VG, Tziomalos K, Gossios TD, et al. Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post hoc analysis. Lancet. 2010;376:1916–1922. doi:10.1016/S0140-6736(10)61272-X.

    Article  CAS  PubMed  Google Scholar 

  55. Dunn W, Xu R, Wingard DL, et al. Suspected nonalcoholic fatty liver disease and mortality risk in a population-based cohort study. Am J Gastroenterol. 2008;103:2263–2271.

    Article  PubMed  PubMed Central  Google Scholar 

  56. Chalasani N. Statins and hepatotoxicity: focus on patients with fatty liver. Hepatology. 2005;41:690–695. doi:10.1002/hep.20671.

    Article  CAS  PubMed  Google Scholar 

  57. Cohen DE, Anania FA, Chalasani N, National Lipid Association Statin Safety Task Force Liver Expert P. An assessment of statin safety by hepatologists. Am J Cardiol. 2006;97:77C–81C. doi:10.1016/j.amjcard.2005.12.014.

    Article  CAS  PubMed  Google Scholar 

  58. Athyros VG, Mikhailidis DP, Didangelos TP, et al. Effect of multifactorial treatment on non-alcoholic fatty liver disease in metabolic syndrome: a randomised study. Curr Med Res Opin. 2006;22:873–883. doi:10.1185/030079906X104696.

    Article  CAS  PubMed  Google Scholar 

  59. Ekstedt M, Franzen LE, Mathiesen UL, Holmqvist M, Bodemar G, Kechagias S. Statins in non-alcoholic fatty liver disease and chronically elevated liver enzymes: a histopathological follow-up study. J Hepatol. 2007;47:135–141. doi:10.1016/j.jhep.2007.02.013.

    Article  CAS  PubMed  Google Scholar 

  60. Nelson A, Torres DM, Morgan AE, Fincke C, Harrison SA. A pilot study using simvastatin in the treatment of nonalcoholic steatohepatitis: a randomized placebo-controlled trial. J Clin Gastroenterol. 2009;43:990–994. doi:10.1097/MCG.0b013e31819c392e.

    Article  CAS  PubMed  Google Scholar 

  61. Foster T, Budoff MJ, Saab S, Ahmadi N, Gordon C, Guerci AD. Atorvastatin and antioxidants for the treatment of nonalcoholic fatty liver disease: the St Francis Heart Study randomized clinical trial. Am J Gastroenterol. 2011;106:71–77. doi:10.1038/ajg.2010.299.

    Article  CAS  PubMed  Google Scholar 

  62. Corey KE, Chalasani N. Management of dyslipidemia as a cardiovascular risk factor in individuals with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2014;12:1077–1084.

    Article  PubMed  PubMed Central  Google Scholar 

  63. Spadaro L, Magliocco O, Spampinato D, et al. Effects of n-3 polyunsaturated fatty acids in subjects with nonalcoholic fatty liver disease. Dig Liver Dis. 2008;40:194–199. doi:10.1016/j.dld.2007.10.003.

    Article  CAS  PubMed  Google Scholar 

  64. Zhu FS, Liu S, Chen XM, Huang ZG, Zhang DW. Effects of n-3 polyunsaturated fatty acids from seal oils on nonalcoholic fatty liver disease associated with hyperlipidemia. World J Gastroenterol (WJG). 2008;14:6395–6400.

    Article  CAS  Google Scholar 

  65. Cussons AJ, Watts GF, Mori TA, Stuckey BG. Omega-3 fatty acid supplementation decreases liver fat content in polycystic ovary syndrome: a randomized controlled trial employing proton magnetic resonance spectroscopy. J Clin Endocrinol Metab. 2009;94:3842–3848. doi:10.1210/jc.2009-0870.

    Article  CAS  PubMed  Google Scholar 

  66. Scorletti E, Bhatia L, McCormick KG, et al. Effects of purified eicosapentaenoic and docosahexaenoic acids in nonalcoholic fatty liver disease: results from the Welcome* study. Hepatology. 2014;60:1211–1221. doi:10.1002/hep.27289.

    Article  CAS  PubMed  Google Scholar 

  67. Argo CK, Patrie JT, Lackner C, et al. Effects of n-3 fish oil on metabolic and histological parameters in NASH: a double-blind, randomized, placebo-controlled trial. J Hepatol. 2015;62:190–197. doi:10.1016/j.jhep.2014.08.036.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  68. Dasarathy S, Dasarathy J, Khiyami A, Yerian L, McCullough AJ. Double-blind randomized placebo-controlled clinical trial of omega 3 fatty acids for the treatment of diabetic patients with nonalcoholic steatohepatitis. J Clin Gastroenterol. 2015. doi:10.1097/MCG.0000000000000451.

    PubMed  PubMed Central  Google Scholar 

  69. Sanyal AJ, Abdelmalek MF, Suzuki A, Cummings OW, Chojkier M, Group E-AS. No significant effects of ethyl-eicosapentanoic acid on histologic features of nonalcoholic steatohepatitis in a phase 2 trial. Gastroenterology. 2014;147:377 e1–384 e1. doi:10.1053/j.gastro.2014.04.046.

    Article  PubMed  Google Scholar 

  70. de Jonge C, Rensen SS, Koek GH, et al. Endoscopic duodenal-jejunal bypass liner rapidly improves plasma parameters of nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2013;11:1517–1520. doi:10.1016/j.cgh.2013.07.029.

    Article  PubMed  Google Scholar 

  71. Ricci G, Bersani G, Rossi A, Pigo F, De Fabritiis G, Alvisi V. Bariatric therapy with intragastric balloon improves liver dysfunction and insulin resistance in obese patients. Obes Surg. 2008;18:1438–1442. doi:10.1007/s11695-008-9487-x.

    Article  PubMed  Google Scholar 

  72. Lee YM, Low HC, Lim LG, et al. Intragastric balloon significantly improves nonalcoholic fatty liver disease activity score in obese patients with nonalcoholic steatohepatitis: a pilot study. Gastrointest Endosc. 2012;76:756–760. doi:10.1016/j.gie.2012.05.023.

    Article  PubMed  Google Scholar 

  73. Taitano AA, Markow M, Finan JE, Wheeler DE, Gonzalvo JP, Murr MM. Bariatric surgery improves histological features of nonalcoholic fatty liver disease and liver fibrosis. J Gastrointest Surg. 2015;19:429–436. doi:10.1007/s11605-014-2678-y. (discussion 36–37).

    Article  PubMed  Google Scholar 

  74. Dixon JB, Bhathal PS, O’Brien PE. Weight loss and non-alcoholic fatty liver disease: falls in gamma-glutamyl transferase concentrations are associated with histologic improvement. Obes Surg. 2006;16:1278–1286. doi:10.1381/096089206778663805.

    Article  PubMed  Google Scholar 

  75. Mummadi RR, Kasturi KS, Chennareddygari S, Sood GK. Effect of bariatric surgery on nonalcoholic fatty liver disease: systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2008;6:1396–1402. doi:10.1016/j.cgh.2008.08.012.

    Article  PubMed  Google Scholar 

  76. Mattar SG, Velcu LM, Rabinovitz M, et al. Surgically-induced weight loss significantly improves nonalcoholic fatty liver disease and the metabolic syndrome. Ann Surg. 2005;242:610–617. (discussion 18–20).

    PubMed  PubMed Central  Google Scholar 

  77. Peterli R, Wolnerhanssen B, Peters T, et al. Improvement in glucose metabolism after bariatric surgery: comparison of laparoscopic Roux-en-Y gastric bypass and laparoscopic sleeve gastrectomy: a prospective randomized trial. Ann Surg. 2009;250:234–241. doi:10.1097/SLA.0b013e3181ae32e3.

    Article  PubMed  Google Scholar 

  78. Stylopoulos N, Hoppin AG, Kaplan LM. Roux-en-Y gastric bypass enhances energy expenditure and extends lifespan in diet-induced obese rats. Obesity. 2009;17:1839–1847. doi:10.1038/oby.2009.207.

    Article  PubMed  PubMed Central  Google Scholar 

  79. Liou AP, Paziuk M, Luevano JM Jr, Machineni S, Turnbaugh PJ, Kaplan LM. Conserved shifts in the gut microbiota due to gastric bypass reduce host weight and adiposity. Sci Transl Med. 2013;5:178ra41. doi:10.1126/scitranslmed.3005687.

    PubMed  PubMed Central  Google Scholar 

  80. Gerhard GS, Styer AM, Wood GC, et al. A role for fibroblast growth factor 19 and bile acids in diabetes remission after Roux-en-Y gastric bypass. Diabetes Care. 2013;36:1859–1864. doi:10.2337/dc12-2255.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Gastrointestinal Unit, Liver Center, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA

    Kathleen E. Corey & Mary E. Rinella

  2. Department of Gastroenterology and Hepatology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA

    Kathleen E. Corey & Mary E. Rinella

Authors
  1. Kathleen E. Corey
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mary E. Rinella
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kathleen E. Corey.

Ethics declarations

Conflict of interest

The authors have no conflict to disclose.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Corey, K.E., Rinella, M.E. Medical and Surgical Treatment Options for Nonalcoholic Steatohepatitis. Dig Dis Sci 61, 1387–1397 (2016). https://doi.org/10.1007/s10620-016-4083-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10620-016-4083-8

Keywords

Search

Navigation